Last €193.33 EUR
Change Today -0.65 / -0.34%
Volume 6.0
SP2 On Other Exchanges
Symbol
Exchange
SP2 is not on other exchanges.
As of 3:18 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SP2) Snapshot

Open
€191.71
Previous Close
€193.99
Day High
€194.09
Day Low
€190.64
52 Week High
10/6/14 - €210.25
52 Week Low
04/14/14 - €99.50
Market Cap
38.0B
Average Volume 10 Days
2.6
EPS TTM
--
Shares Outstanding
196.7M
EX-Date
09/3/14
P/E TM
--
Dividend
€0.20
Dividend Yield
0.24%
Current Stock Chart for SHIRE PLC-ADR (SP2)

shire plc-adr (SP2) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

5,338 Employees
Last Reported Date: 02/24/14
Founded in 1986

shire plc-adr (SP2) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc-adr (SP2) Key Developments

Shire plc Receives United States Food and Drug Administration Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome

Shire plc announced that the United States Food and Drug Administration has granted Fast Track designation for SHP609 (idursulfase-IT; also known as HGT-2310) for the treatment of neurocognitive decline associated with Hunter syndrome (mucopolysaccharidosis II or MPSII). This investigational formulation of idursulfase has been designed for direct administration into the cerebrospinal fluid via an intrathecal drug delivery device(IDDD). This formulation is being investigated and developed for use with Shire's currently approved treatment for Hunter syndrome, ELAPRASE (idursulfase). ELAPRASE is administered intravenously and does not cross the blood-brain barrier in clinically relevant amounts. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs that address serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designation provides increased opportunities to interact and meet with FDA, and increases the likelihood of being eligible for priority review if supported by clinical data at the time of BLA.

Shire plc to Expand Lexington Campus; to Move Workers to Two Ledgemont Center Site

Drug giant Shire PLC has signed a lease in Lexington that will create large biotechnology campus. The company will move hundreds of its employees into an office building at Two Ledgemont Center, which will be part of an expanded US headquarters for Shire covering about 900,000 square feet. The company already occupies several buildings in the adjacent Lexington Technology Park. In its latest deal, the company will lease the entire five-floor building at Two Ledgemont Center, which has most recently served as the headquarters for Vistaprint. Shire intends to move its employees into Two Ledgemont Center in 2016. As part of the deal, Transwestern RBJ negotiated interim office space for Shire at 235 Wyman St.

Vertex Pharmaceuticals Could Be The Target For Shire

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) could be the possible target for the Shire plc (LSE:SHP) next acquisition, Bloomberg said.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SP2:GR €193.33 EUR -0.65

SP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $219.26 USD -3.13
Astellas Pharma Inc ¥1,830 JPY +6.50
CSL Ltd A$87.95 AUD +0.38
Mylan Inc/PA $53.15 USD -1.73
Valeant Pharmaceuticals International Inc C$203.17 CAD -0.46
View Industry Companies
 

Industry Analysis

SP2

Industry Average

Valuation SP2 Industry Range
Price/Earnings 23.8x
Price/Sales 7.5x
Price/Book 6.6x
Price/Cash Flow 33.6x
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.